【摘要】 当前治疗抑郁症的主流药物有选择性5羟色胺(5-HT)摄取抑制剂(SSRIs)和5-HT、去甲肾上腺素(NE)双重再摄取抑制剂(SNRIs);临床使用过程中存在起效缓慢、快感缺乏、认知功能低下和性功能障碍等缺陷;临床前和临床研究显示,在SNRIs的基础上加入多巴胺(DA)摄取抑制的5-HT/NE/DA三重再摄取抑制剂(SNDRIs)能够改善目前药物存在的治疗缺陷。盐酸安舒法辛为一种全新的SNDRIs,通过不均衡抑制5-HT/NE/DA再摄取发挥抗抑郁作用,预期在临床应用上将具有起效快,改善患者快感缺乏和性功能障碍,增加认知、奖励激励驱动和目标导向行为等特点。更多还原

【Abstract】 The predominant pharmacotherapy of major depressive disorder(MDD) is serotonin(5-HT)selective reuptake inhibitors( SSRIs) or 5-HT /norepinephrine( NE) reuptake inhibitors( SNRIs),which have been approved to improve the patients’ compliance. However,SSRIs and /or SNRIs display slow onset and cannot alleviate anhedonia,cognitive impairment and sexual dysfunction. Based on the preclinical and clinical studies,the5-HT /NE /dopamine(DA) reuptake inhibitors(SNDRIs),which could increase DA,NE and 5-HT in the synaptic cleft,might provide superior efficacy in MDD treatment and overcome the shortcomings associated with SSRIs and SNRIs. Ansofaxine hydrochloride was developed as a novel SNDRI with unbalanced inhibitory activity against the reuptakes of DA,NE and 5-HT,and is expected to display marked improvements in patients with MDD in clinic.更多还原